ArticleGastroHep2020
The effects of COVID-19 on IBD prescribing and service provision in a UK tertiary centre.
Article in GastroHep, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- The impact of COVID-19 on inflammatory bowel disease surgery: a systematic review.Annals of the Royal College of Surgeons of England · 2026Pooled it
- Comparative analysis of inflammatory bowel disease (IBD) patient- and service-reported quality of care using 2019 and 2023 UK benchmarking data from more than 26 000 adult patient respondents and 154 IBD services.Journal of Crohn's & colitis · 2026Article
- Effectiveness of telehealth versus in-person care during the COVID-19 pandemic: a systematic review.NPJ digital medicine · 2024Review
- Inpatient outcomes of inflammatory bowel disease in hospitalized patients with COVID-19: analysis of a nationally representative sample.Proceedings (Baylor University. Medical Center) · 2024Article
- Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study.Alimentary pharmacology & therapeutics · 2022Observational
- Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic.Frontline gastroenterology · 2022Article
- Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Health Care Delivery During the Pandemic and the Future Model of Inflammatory Bowel Disease Care.Journal of the Canadian Association of Gastroenterology · 2021Article
- COVID-19: Effect on gastroenterology and hepatology service provision and training: Lessons learnt and planning for the future.World journal of gastroenterology · 2021Review
- The Particularities of Pharmaceutical Care in Improving Public Health Service during the COVID-19 Pandemic.International journal of environmental research and public health · 2021Review
- Quality of life in patients with IBD during the COVID-19 pandemic in the Netherlands.BMJ open gastroenterology · 2021Article
- The effects of COVID-19 on IBD prescribing and service provision in a UK tertiary centre.GastroHep · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo quantify the effects of COVID-19 on our inflammatory bowel disease (IBD) unit, including service provision, prescribing practices and use of therapeutic drug monitoring (TDM).
methodsWe performed a single centre retrospective observational cohort study. Data was extracted from our IBD database, electronic patient records and radiology/endoscopy reporting systems between 16/3/20-17/4/20 and the corresponding period in 2019.
resultsA similar number of patients commenced biologic therapy before COVID-19 (n = 37) and during the pandemic (n = 36). Patients in the pre-COVID-19 cohort were older (median 36 vs 29 years,
conclusionsWe observed prescribing differences during COVID-19, bypassing the initiation of immunomodulators and/or anti-TNF therapy in favour of vedolizumab with a reduction in immunomodulator prescribing. We also observed a rapid reorganisation of service provision, including a shift towards telemedicine and online solutions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.